Volume 25, Issue 6 (Aug 2017)
JSSU 2017, 25(6): 476-484 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abdolrezaee H, Reiisi S, Rouhi L. Study of the expression of TUSC1 (Tumor suppressor candidate gene 1) in breast cancer tissue samples and correlation with tumorgenesis. JSSU 2017; 25 (6) :476-484
URL: http://jssu.ssu.ac.ir/article-1-4172-en.html
URL: http://jssu.ssu.ac.ir/article-1-4172-en.html
Abstract: (4912 Views)
Introduction: Breast cancer remains the prominent cause of mortality in women. Several biomarkers are used to evaluation the response and targeting to therapy. Tumor suppressor candidate 1 (TUSC1) gene was newly identified as a probable tumor suppressor in human cancers. Nevertheless, the expression and potential function of TUSC1 in breast cancer stay undecided. Therefore, this study aimed the evaluation of TUSC1 gene expression in breast tumor samples.
Methods: In this case-control study, 40 formalin-fixed paraffin embedded (FFPE) tumoral of breast cancer and 40 healthy tissues were enrolled. Followed were informed consent and completing clinical information for all samples. Total RNA was extracted and complementary DNA (cDNA) was synthesized. The relative gene expression was determined using quantitative real-time RT PCR (qRT-PCR) and evaluated by method.
Results: The expression of TUSC1 gene was lower in tumor tissue compared to the healthy tissue adjacent and it was statistically significant (P =0.0003). Also, in metastatic state gene expression significantly decreased (P=0.027).
Conclusion: Our study revealed that the expression of TUSC1 is lower in breast cancer. Subsequently, using considering all the data about the expression of TUSC1 gene from some cancers (e.g. Lung, Hepatocellular and gastric), it could be suggested that the TUSC1 gene might act as a tumor suppressor in breast cancer and influenced in metastasis. Therefore, supplementary studies should be done to elucidate the exact mechanism of action of the gene in tumor-genesis
Methods: In this case-control study, 40 formalin-fixed paraffin embedded (FFPE) tumoral of breast cancer and 40 healthy tissues were enrolled. Followed were informed consent and completing clinical information for all samples. Total RNA was extracted and complementary DNA (cDNA) was synthesized. The relative gene expression was determined using quantitative real-time RT PCR (qRT-PCR) and evaluated by method.
Results: The expression of TUSC1 gene was lower in tumor tissue compared to the healthy tissue adjacent and it was statistically significant (P =0.0003). Also, in metastatic state gene expression significantly decreased (P=0.027).
Conclusion: Our study revealed that the expression of TUSC1 is lower in breast cancer. Subsequently, using considering all the data about the expression of TUSC1 gene from some cancers (e.g. Lung, Hepatocellular and gastric), it could be suggested that the TUSC1 gene might act as a tumor suppressor in breast cancer and influenced in metastasis. Therefore, supplementary studies should be done to elucidate the exact mechanism of action of the gene in tumor-genesis
Type of Study: Original article |
Subject:
Genetics
Received: 2017/04/20 | Accepted: 2017/09/16 | Published: 2017/11/1
Received: 2017/04/20 | Accepted: 2017/09/16 | Published: 2017/11/1
References
1. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA: a cancer j clinicians 2016; 66(1): 31-42.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer j clinicians 2005; 55(2): 74-108.
3. Karami F, Mehdipour P. A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer. BioMed research international 2013; 2013.
4. Berek JS. Novak's gynecology. Journal of Midwifery & Women’s Health. 2003; 48(3): 237-8.
5. Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Archiv 2014; 465(1): 1-14.
6. Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen S-L. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 2011; 13(1): 20.
7. Dunn BK, Wagner PD, Anderson D, Greenwald P, editors. Molecular markers for early detection. Seminars in oncology 2010: 37(3): 224-42 Elsevier.
8. Shan Z, Parker T, Wiest JS. Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer. Oncogene 2004; 23(39): 6612-20.
9. Kanda M, Shimizu D, Nomoto S, Hibino S, Oya H, Takami H, et al. Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer. J surgical oncology 2014; 110(2): 136-44.
10. Shimizu D, Kanda M, Nomoto S, Oya H, Takami H, Hibino S, et al. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncology reports 2014; 31(3): 1305-13.
11. Shan Z, Shakoori A, Bodaghi S, Goldsmith P, Jin J, Wiest JS. TUSC1, a putative tumor suppressor gene, reduces tumor cell growth in vitro and tumor growth in vivo. PloS one 2013; 8(6): e66114.
12. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486(7403): 400-4.
13. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol 2014; 5(3): 283-98.
14. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA: a cancer j clinicians 2014; 64(4): 252-71.
15. Zhang R, Yu W, Liang G, Jia Z, Chen Z, Zhao L, et al. Tumor Suppressor Candidate 1 Suppresses Cell Growth and Predicts Better Survival in Glioblastoma. Cellular and molecular neurobiology 2017; 37(1): 37-42.
16. Huang K, Chen L, Zhang J, Wu Z, Lan L, Wang L, et al. Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma. Oncology letters 2014; 8(4): 1441-6.
17. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D’Souza C, Fouse SD, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010; 466(7303): 253-7.
18. Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, Rao K, et al. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer research 1997; 57(1): 1-6.
19. Mead LJ, Gillespie MT, Hung JY, Rane US, Rayeroux KC, Irving LB, et al. Frequent loss of heterozygosity in early non‐small cell lung cancers at chromosome 9p21 proximal to the CDKN2a gene. International j cancer 1997; 71(2): 213-7.
20. Pollock PM, Welch J, Hayward NK. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer research 2001; 61(3): 1154-61.
21. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature genetics 1995; 11(2): 210-2.
22.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
